Navigation Links
New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
Date:12/21/2007

iving tolvaptan vs. 3.9% in patients receiving placebo). For all of these, the number of patients that received tolvaptan was 2063 and for placebo was 2055 in addition to standard of care.

About Heart Failure

More than 14 million people in Europe(3) and five million U.S. residents(4) have heart failure (HF), a serious chronic condition in which the heart cannot effectively pump blood. Hospitalizations in the United States related to HF account for 75 percent of the $46 billion spent each year on the care of HF patients, according to the American Heart Association.(5) The majority of patients hospitalized for worsening HF, about 1 million U.S. residents annually, have edema or excess body fluid.

About Hyponatremia

Hyponatremia, characterized by low concentrations of sodium in the blood, is a known predictor of death in patients with serious underlying illnesses.(6) Hyponatremia has long been associated with neurological symptoms including in its worst forms seizure and coma, and in its mildest forms slowed thoughts and reflexes.(7) Normal serum sodium is between 135 to 145 mEq/L, whereas patients diagnosed with hyponatremia have sodium levels of less than 135 mEq/L.(8)

About Otsuka Pharmaceutical Development & Commercialization, Inc.

Otsuka Pharmaceutical Development & Commercialization (OPDC) is involved in conducting all phases of clinical research and development of innovative healthcare products to address unmet medical needs. OPDC is well established in the scientific community as a globally focused organization that plays a leadership role in the research and development of Otsuka's ethical healthcare products. The Company is dedicated to the improvement of the quality of human life and health of patients around the world with a strong commitment to research and development in the areas of cardiovascular, neuroscience, renal and respiratory diseases, as well as cancer and ophthalmic disorders. The Company is part of the
'/>"/>

SOURCE Otsuka Pharmaceutical Development & Commercialization,Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
3. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
4. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
5. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
8. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
11. Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Bedford, NH (PRWEB) January 22, 2015 ... offers a table top laboratory homogenizer, the PandaPLUS 2000, ... nanoparticles, nanodispersions, nanoemulsions , and cell disruption . ... processing dairy products, fruit juices, liquid food, food additives ...
(Date:1/22/2015)... January 22, 2015 Protocol Networks brings ... growing team of brand-neutral, independent consultants, Protocol Networks has ... explained that over the years, his company has attracted ... Town of Plainfield, as well as others. With the ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... 12 Epeius Biotechnologies Corporation today announced more stunning ... world,s first and, so far only, tumor-targeted genetic medicine ... therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has ... much-touted biologics have failed to do: that is, to ...
... ImaginAb, Inc. and BZL Biologics, LLC have concluded ... field of diagnostic imaging for PET and SPECT. "ImaginAb ... BZL as we believe that huJ591 will form the ... and management of prostate cancer. BZL,s technology has extensive ...
... Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: ... treatment phase of its open-label Phase 2a clinical trial ... with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver ... U.S. population. At the completion of the initial six-month ...
Cached Biology Technology:Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 2Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 3ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA) 2Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 2Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 3Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 4Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 5Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 6
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... http://photos.prnewswire.com/prnh/20130307/600769 ... introduced the fingerprint reading feature with the iPhone 5S. ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading personal ... pinpoints fine-scale differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... meeting place for peoples from different continents. This study illuminates ...
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... copper industry is working together to answer one very ... bronze) help curb the spread of bacteria that cause ... indicate that they can. Scientists from around the world ... and Public Health, on copper,s role in fighting the ...
... 2009 Responding to the growing popularity of a ... it is developing a new standard to be included ... food and beverage manufacturers assure the product,s quality for ... beverage industry as well as all other interested parties ...
... filament lamin A/C (LMNA) gene are associated with Emery-Dreifuss muscular ... al. show that one mechanism involves the disruption of neuromuscular ... January 5, 2009 ( www.jcb.org ) and in the January ... Biology . Muscle fiber cells contain hundreds of ...
Cached Biology News:International copper industry defines role in the fight against hospital infections 2New standard for popular stevia-based sweetener to assure product's quality 2
...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
... DNase I Amplification ... double-stranded DNA to oligodeoxyribonucleotides. ... >10000 units/mg. DNAse I ... purified and tested for ...
Biology Products: